期刊文献+

SBP1和Caspase-3在人乳腺癌组织中的表达及意义 被引量:4

Expression and significance of SBP1 and Caspase-3 in human breast cancer
下载PDF
导出
摘要 目的观察人乳腺癌组织中硒结合蛋白1(SBP1)和凋亡调节蛋白(Caspase-3)的表达,探讨SBP1和Caspase-3在乳腺癌发生、发展过程中的作用及其相互关系。方法用免疫组织化学ABC法检测乳腺癌中SBP1和Caspase-3的表达水平,并与癌旁相对正常组织、乳腺良性病变组织进行比较分析。结果 SBP1、Caspase-3在癌旁相对正常乳腺组织中的阳性表达率为100%、86.6%;在乳腺良性病变组织的阳性表达率为93.3%、73.3%;在乳腺癌组织的阳性表达率为82.1%、57.1%。乳腺癌组织中SBP1和Caspase-3的表达水平均明显低于癌旁相对正常组织和乳腺良性病变组织。乳腺癌组织中SBPl与Caspase-3的表达呈正相关。结论乳腺癌组织中SBP1和Caspase-3的表达下调,提示SBPl可能通过促进肿瘤细胞的凋亡来抑制肿瘤的增殖,为进一步对硒诱导SBP1治疗乳腺癌的作用研究提供基础。 Objective To investigate the relationship of the expression of SBP1 and Caspase-3 in human breast cancer. Methods The human breast cancer tissues, para-carcinoma breast tissues and breast benign lesions were collected, the expres- sion of SBP1 and Caspase-3 in tissues were detected by immunohistochemistry, and the correlation between SBP1 and Caspase-3 were assessed by statistical approach. Results The expression rate of SBP1 and Caspase-3 were 100% and 86.6% in para- carcinoma breast tissues, 93.3% and 73.3% in breast benign lesions, 82.1% and 57.1% in breast cancer tissues, respectively. Expression rate of SBP1 and Caspase-3 in breast cancer tissues was significantly lower than that in para- carcinoma breast tis- sues and breast benign lesions (P〈0.05). SBP1 and Caspase-3 expressions were positively correlated(P〈0.05). Conclusion Down-regulation of SBP1 and Caspase-3 in breast cancer tissues suggest that SBP1 may inhibit tumor growth by promoting apop- tosis of tumor ceils, which may provide a basis for future studies to use selenium to treat breast cancer.
出处 《解剖学研究》 CAS 2014年第1期39-42,共4页 Anatomy Research
基金 广东省科技计划项目(2012B031800311)
关键词 硒结合蛋白1 调亡调节蛋白3 乳腺癌 免疫组织化学 Seleium binding protein 1, SBP1 Caspase-3 Breast cancer Immunohistochemistry
  • 相关文献

参考文献18

  • 1Combs GF Jr. Current evidence and research needs to support a health Claim for selenium and cancer.preven- tion. J Nutr, 2005,135(2) :343-347.
  • 2Brinkman M, Buntinx F, Muls E, et al. Use of selenium in chemoprevention of bladder cancer. Lancet Oncol, 2006,7 (9) : 766-774.
  • 3Behne D, Kyriakopoulos A. Mammalian selenium-con- taining proteins. Annu Rev Nutr, 2001,21:453-473.
  • 4Stammer K, Edassery SL, Barua A, et al. Selenium-Bind- ing Protein 1 expression in ovaries and ovarian tumors of in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol, 2008,109( 1 ) : 115-121.
  • 5Zhang P, Zhang C, Wang X, et aL. The expression of selenium-binding protein 1 is decreased in uterine leiomyoma. Diagn Pathol, 2010,9 (5) : 80.
  • 6Chen G, Wang H, Miller CT, et al. Reduced selenium-binding protein 1 expression is associated with poor out- come in lung adenocarcinomas. J Pathol, 2004,202 (3) : 321-329.
  • 7Silvers AL, Lin L, Bass A J, et al. Decreased selenium- binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and af- fects chemosensitivity. Clin Cancer Res, 2010,16(7): 2009-2021.
  • 8Zhang J, Zhan N, Dong WG. Altered expression of sele- nium-binding protein 1 in gastric carcinoma and precursor lesions. Med Oncol, 2011,28 (4) : 951-957.
  • 9宋彦,宋永胜.凋亡相关蛋白Fas及caspase-3在膀胱移行细胞癌中表达及临床意义[J].肿瘤,2007,27(6):465-468. 被引量:5
  • 10何洁华,梁小曼,候景辉,黄亦莉,吴秋良,肖永波.乳腺导管内乳头状瘤及其癌变组织CD44v6蛋白表达的研究[J].癌症,2002,21(6):615-618. 被引量:18

二级参考文献31

  • 1薛丽燕,任立群,罗巍,管向军,邹霜梅,郑闪,毕蕊,谢永强,何祖根,吕宁.Fas、Fas配体、Fas相关死亡结构域蛋白、天冬氨酸特异性半胱氨酸蛋白酶8和突变型P53蛋白在食管鳞癌患者中的表达[J].中华医学杂志,2007,87(3):150-154. 被引量:18
  • 2[1]Naot D,Sionov RV,Ish Shalom D. CD44:structure,function,and assiociation with the malignant process [J]. Adv Cancer Res,1997,71:241- 319.
  • 3[2]Herrera Gayol A,Jothy S. Adhesion protein in the biology of breast cancer: contribution of CD44 [J]. Exp Mol Pathol,1999,66(2):149- 156.
  • 4[3]Kaufmann M,Heider KH,Sinn HP,et al. CD44 variant exon epitpes in primary breast cancer and length of survival [J]. Lancet,1995,345(8950):615- 619.
  • 5[4]Dall P,Herider KH,Sinn HP,et al. Comparison of immunohistochemistry and RT PCR for detection of CD44v expression,a new prognostic factor in human breast cancer [J]. Int J Cancer,1995,60(4):471- 477.
  • 6[5]Rosen PP,Oberman HA. Tumors of the Mammary Gland [M]. Washington D.C: Armed Forces Institute of Pathology,1992,72- 76.
  • 7[6]Papotti M,Eusebi V,Gugliotta P,et al. Immunohistochemical analysis of benign and malignant papillary lesions of the breast [J]. Am J Surg Pathol,1983,7(5):451- 461.
  • 8[7]Mackay CR,Terpe HJ,Stauder R,et al. Expression and modulation of CD44 variant isoforms in humans [J]. J Cell Biol,1994,124(1- 2):71- 82.
  • 9[8]Mastsumura Y,Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation [J]. Lancet,1992,340(8827):1053- 1058.
  • 10[9]Bankfalvi A,Terpe HJ,Breukelmann D,et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression [J]. Histopathology,1998,33(2):107- 116.

共引文献67

同被引文献61

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部